Neuroendocrine Tumors of Old Patients in the West of France

Neuroendocrine Tumors of Patients Aged of 75 y or Over in the West of France

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03749681

Acronym

TANGO

Enrollment

306

Registered

2018-11-21

Start date

2018-12-31

Completion date

2020-03-28

Last updated

2018-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroendocrine Tumors

Keywords

Neuroendocrine Tumors, 75 y and over patients, Oncogeriatric follow-up, Oncologic care

Brief summary

Neuroendocrine cancer remains a poorly known entity. Comprehensive treatment is multidisciplinary involving surgery, radiological and nuclear medicine, and medical. A national network for the management of sporadic and hereditary malignant neuro-ENdocrine Tumor (RENATEN) is in charged of coordinating this specific care. This is part of the French National Cancer INstitute (INCa) Rare Cancer Plan. The project is in the form of an analysis of elderly population (75 years or over) with a diagnosis of neuroendocrine cancer in the western part of the France (Brittany, Pays de Loire, Normandy, Center and a part of New Aquitaine areas) representing a population of more than 12 millions of inhabitants. Oncogeriatric evaluations, specialized meetings, ...would be analysed in order to improve the care of rare cancer patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

75 Years to No maximum

Healthy volunteers

Inclusion criteria

* 75 years old or over at the time of diagnosis * Patient with G1/G2/G3 neuroendocrine tumor diagnosed by pathological analysis * Patient whose medical file was examined by RENATEN (National Network for the treatment of neuro-ENdocrine sporadic and hereditary disease Tumor) meetings or other multidisciplinary consultation meeting between 01/01/2014 and 31/12/2017 * Patient with care in private and public centers in the West of France

Exclusion criteria

* Patient with cancer other than a neuroendocrine tumor * Patient with a G4 neuroendocrine tumor * Patient who has objected to the study and collection of his medical data * Refusal of participation

Design outcomes

Primary

Measure	Time frame	Description
Tumor description : localization of the tumor (digestive or others) provided by scan or anatomopathologic report	03/31/2020	statistical analysis (%)
All anticancer treatment description in neuroendocrine tumors of 3 specific histological grade (G1, 2 or 3)	03/31/2020	statistical analysis (%)
Histology, differentiation status	03/31/2020	qualitative description (text)
mitotic index and proliferation idex of the tumor	03/31/2020	statistical analysis (%)
Response rate	03/31/2020	statistical analysis (%)
progression free survival	03/31/2020	statistical analysis (months) with Kaplan meier analysis; data provided by the medical file
overall survival	03/31/2020	statistical analysis (months) with Kaplan meier analysis; data provided by the medical file

Countries

France

Contacts

Primary ContactJean-Philippe METGES

jean-philippe.metges@chu-brest.fr02-98-22-33-62

Backup ContactDelphine DENIEL LAGADEC

+33 2 98 22 39 80

Outcome results